Are P2Y12 reaction unit (PRU) and % inhibition index equivalent for the expression of P2Y12 inhibition by the VerifyNow® assay? Role of haematocrit and haemoglobin levels

被引:28
|
作者
Voisin, Sophie [1 ,2 ]
Bongard, Vanina [2 ,3 ]
Tidjane, Mohammed A. [2 ,4 ]
Lhermusier, Thibault [2 ,4 ]
Carrie, Didier [2 ,4 ]
Sie, Pierre [1 ,2 ,5 ]
机构
[1] CHU Toulouse, Haematol Lab, Toulouse, France
[2] Univ Toulouse 3, F-31062 Toulouse, France
[3] CHU Toulouse, Dept Epidemiol, Toulouse, France
[4] CHU Toulouse, Dept Cardiol, Toulouse, France
[5] CHU Toulouse, INSERM, U1048, Toulouse, France
关键词
VerifyNow (R); P2Y(12) assay; haematocrit; haemoglobin; PERCUTANEOUS CORONARY INTERVENTION; OF-CARE ASSAY; PLATELET REACTIVITY;
D O I
10.1160/TH11-01-0046
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The results of the whole blood VerifyNow (R) P2Y(12) assay can be expressed as platelet reaction units (PRU) or % inhibition index ((%)inh), but an optimal cut-off for the assessment of high on-treatment platelet reactivity (HPR) predictive of clinical events has been validated only for PRU. The aim of the study was to study the influence of haematological variables, such as platelet and leukocyte counts or haematocrit / haemoglobin, within the limits indicated by the manufacturer for assay validity, on the results of the test. We performed a comparison of PRU and (%)inh in a series 186 samples obtained from a clinical trial on patients under dual antiplatelet therapy. The results show that PRU significantly decreases with increasing haematocrit / haemoglobin, whereas (%)inh does not, due to a parallel change in PRU and iso-TRAP baseline value. PRU and % inhibition index are not equivalent for the definition of HPR, because of their different sensitivities to haematocrit / haemoglobin.
引用
收藏
页码:227 / 229
页数:3
相关论文
共 50 条
  • [1] Hirudin anticoagulation allows more rapid determination of P2Y12 inhibition by the VerifyNow P2Y12 assay
    Sumaya, Wael
    Daly, Rebecca L.
    Mehra, Sonal
    Dhutia, Amrita J.
    Howgego, Kate E.
    Ecob, Rosemary
    Judge, Heather M.
    Morton, Allison C.
    Storey, Robert F.
    THROMBOSIS AND HAEMOSTASIS, 2013, 109 (03) : 550 - 555
  • [2] P2y12 Reaction Unit (PRU), Baseline Value, and % Inhibition From VerifyNow System Are Influenced by Hemoglobin Level
    Youn, Young Jin
    Kim, Kyung-Min
    Lee, Ji Hyun
    Lee, Jun-Won
    Ahn, Sung Gyun
    Ahn, Min-Soo
    Kim, Jang-Young
    Yoo, Byung-Su
    Lee, Seung-Hwan
    Yoon, Junghan
    Choe, Kyung-Hoon
    CIRCULATION, 2013, 128 (22)
  • [3] CORRELATION BETWEEN THE VERIFYNOW P2Y12 ASSAY AND LIGHT TRANSMITTANCE AGGREGOMETRY TO MEASURE PLATELET P2Y12 RECEPTOR INHIBITION IN PATIENTS ON CLOPIDOGREL THERAPY
    Ueno, Masafumi
    Ferreiro, Jose Luis
    Dharmashankar, Kodlipet
    Capranzano, Piera
    Capodanno, Davide
    Darlington, Andrew
    Bhaloo, Desai
    Charlton, Ronald
    Box, Lyndon
    Zenni, Martin
    Guzman, Luis
    Bass, Theodore
    Angiolillo, Dominick J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (10)
  • [4] Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y12 antagonism
    Jakubowski, Joseph A.
    Zhou, Chunmei
    Egan, Blaine
    Wells, Maggie
    Kotob-Yahfoufi, Maya
    Sugidachi, Atsuhiro
    Dahlen, Jeffrey R.
    PLATELETS, 2011, 22 (08) : 619 - 625
  • [5] Assessment of P2Y12 inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin
    Varenhorst, Christoph
    James, Stefan
    Erlinge, David
    Braun, Oscar O.
    Brandt, John T.
    Winters, Kenneth J.
    Jakubowski, Joseph A.
    Olofsson, Sylvia
    Wallentin, Lars
    Slegbahn, Agneta
    AMERICAN HEART JOURNAL, 2009, 157 (03) : 562.e1 - 562.e9
  • [6] Assessment of VerifyNow P2Y12 Assay accuracy in evaluating clopidogrel-induced platelet inhibition
    Lordkipanidze, Marie
    Pharand, Chantal
    Nguyen, Thuy Anh
    Schampaert, Erick
    Diodati, Jean G.
    THERAPEUTIC DRUG MONITORING, 2008, 30 (03) : 372 - 378
  • [7] The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration
    Jakubowski, Joseph A.
    Payne, Christopher D.
    Li, Ying G.
    Brandt, John T.
    Small, David S.
    Farid, Nagy A.
    Salazar, Daniel E.
    Winters, Kenneth J.
    THROMBOSIS AND HAEMOSTASIS, 2008, 99 (02) : 409 - 415
  • [8] Monitoring platelet inhibition induced by P2Y12 receptor blockade:: A comparison of P2Y12 specific assays
    Angiolillo, Domiaick J.
    Desai, Bhaloo
    Hang, Yuan
    Charlton, Ronald
    Bernardo, Esther
    Shoemaker, Steven
    Zenni, Martin
    Guzman, Luis
    Gilmore, Paul
    Bass, Theodore A.
    Costa, Marco A.
    AMERICAN JOURNAL OF CARDIOLOGY, 2006, 98 (8A): : 205M - 206M
  • [9] P2Y12 platelet inhibition in clinical practice
    Damman, Peter
    Woudstra, Pier
    Kuijt, Wichert J.
    de Winter, Robbert J.
    James, Stefan K.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2012, 33 (02) : 143 - 153
  • [10] P2Y12 platelet inhibition in clinical practice
    Peter Damman
    Pier Woudstra
    Wichert J. Kuijt
    Robbert J. de Winter
    Stefan K. James
    Journal of Thrombosis and Thrombolysis, 2012, 33 : 143 - 153